Immune checkpoint inhibitors: pharmacology and toxicities

摘要

Targeting the immune system as a means of activating anti-tumour activity through immune checkpoint inhibition is proving to be an increasingly effective method of treating a variety of cancers, prolonging life and increasing progression-free survival. Consequently, immune checkpoint inhibitors are available for a number of different indications, with the potential of being licensed for further indications in the future (see Table 1).